Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026

Stockholm, May 7, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) today announced that the Company is planning to participate in several upcoming medical conferences in 2026, including:

American Academy of Cerebral Palsy and Developmental Medicine (AACPDM)
Philadelphia, PA, USA
British Thyroid Association (BTA)
London, UK
Child Neurology Society (CNS)
Montreal, Canada
European Society for Paediatric Endocrinology (ESPE)
Marseille, France
European Thyroid Association (ETA)
Porto, Portugal
German Pediatrics Conference (DGKJ)
Berlin, Germany
German Society for Neuropediatrics (GNP)
Linz, Austria
German Society for Pediatric Endocrinology (JA-PED)
Berlin, Germany
Société Française de Pédiatrie (SFP)
Paris, France
Society for Developmental and Behavioral Pediatrics (SDBP)
New Orleans, LA, USA
Society for the Study of Inborn Errors of Metabolism (SSIEM)
Helsinki, Finland
Spanish Society of Paediatric Endocrinology Foundation (FSEEP)
Barcelona, Spain

Nicklas Westerholm, CEO, commented: “Our participation in leading international conferences throughout 2026 reflects our continued focus and commitment on raising awareness of MCT8 deficiency and contributing to the exchange of knowledge around this devastating rare disease.”

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.

The Company’s lead drug candidate Emcitate® (tiratricol) is developed for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In February 2025 the European Commission approved Emcitate® as the first and only treatment for MCT8 deficiency in EU. Egetis initiated the launch of Emcitate® in Germany on May 1, 2025. Emcitate® (tiratricol) is not approved in the USA.

On March 27, 2026, Egetis announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for Emcitate® (tiratricol) for the treatment of MCT8 deficiency. The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date, or FDA decision date, of September 28, 2026.

The NDA for Emcitate® (tiratricol) for treatment of MCT8 deficiency is based on clinical data from Triac Trial I, Triac Trial II, ReTRIACt, EMC Cohort Study, EMC Survival Study and the US Expanded Access Program.

Tiratricol holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Tiratricol has been granted Breakthrough Therapy Designation and Rare Pediatric Disease Designation (RPDD) by the FDA, which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval.

The drug candidate Aladote® (calmangafodipir) is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed. The design of a pivotal Phase IIb/III study (Albatross), with the purpose of applying for market approval in the US and Europe, has been finalized following interactions with the FDA, EMA and MHRA. The development program for Aladote® has been parked. Aladote® has been granted ODD in the US and in the EU.

Egetis Therapeutics is listed on the Nasdaq Stockholm main market (Nasdaq Stockholm: EGTX).
For more information, see www.egetis.com